The medication is commonly used to offer integrated, simultaneous symptomatic support across two main domains of discomfort experienced during a common cold or flu-like illness. The combination is used to address symptom clusters of upper respiratory infections, including headache, fever, body aches, and nasal congestion.

---

Integrated Relief from Cold and Flu Symptoms

This formulation is commonly used across conditions presenting with acute episodes of the cold and influenza, applied when multiple symptoms occur together, and may be part of symptomatic management for: headache, minor aches and pains, elevated body temperature, and nasal or sinus stuffiness. It is relevant in situations where symptoms interfere with daily comfort, generally offering supportive relief that helps patients cope more steadily with difficult episodes.

“Applied in contexts where additional symptomatic support is needed for the systemic and localized manifestations of illness.”

---

Management of Systemic Distress and Congestion

The medication is applied in contexts where additional symptomatic support is needed for the systemic manifestations of illness, as well as the symptoms related to vascular swelling in the upper respiratory tract. By helping to manage the intensity of these symptoms related to systemic imbalance, the preparation may contribute to easing the overall symptom load during periods of heightened physical distress.

---

Quick Fact: Relief for Fever and Congestion

Eligibility Map: Who can and cannot use Coldrex Head Cold — Official Regulatory Information

The eligibility status for Coldrex Head Cold, a combination product of Acetaminophen and Pseudoephedrine, is strictly determined by regulatory documentation.

Section	Classification / Status
Populations for whom use is allowed	Established use in Adults and Adolescents (12 years and older) who do not have documented contraindicating conditions.
Populations for whom use is contraindicated	Patients with severe hypertension or severe coronary artery disease; patients receiving MAO Inhibitors or within 14 days of cessation.
Age-related eligibility rules	Contraindicated for children under 12 years of age. Use in Older Adults (Geriatric) requires specific caution.
Condition-specific eligibility rules	Contraindicated in severe hepatic impairment and severe renal impairment. Caution is required for patients with diabetes mellitus, hyperthyroidism, glaucoma, and prostatic hypertrophy.
Pregnancy and lactation eligibility status	Use is generally not recommended during pregnancy or while breastfeeding.

---

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication; Restricted Use/Caution; Not Recommended.

---

Resulting eligibility structure

Official eligibility statements:

• The medicine is contraindicated in patients with severe hypertension and severe coronary artery disease.
• Individuals taking an MAO Inhibitor must not use this medicine.
• Use is generally not recommended in children under 12 years of age.
• Contraindicated in patients with severe impairment of liver (hepatic) function or kidney (renal) function.

Connection to the overall eligibility profile: Regulatory documents define the eligibility profile by establishing a hierarchy of restrictions, ranging from absolute prohibitions based on severe cardiovascular disease or MAOI use, to categories where use is not recommended (e.g., pregnancy/lactation), and patient groups requiring caution due to coexisting conditions. This ensures use is limited to populations for whom the risk-benefit profile is acceptable under regulated guidelines.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Coldrex Head Cold, which combines Acetaminophen and Pseudoephedrine hydrochloride, based strictly on government regulatory documents.

Interaction scope

Classification
Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Antihypertensive Agents (e.g., Beta-blockers), Tricyclic Antidepressants, Ergot Alkaloids, Cardiac Glycosides, Urinary Alkalinizing Agents, Oral Anticoagulants.
Specific interacting medicines (if explicitly listed): Alcohol (Ethanol), Other Acetaminophen-Containing Products, Warfarin, Metoclopramide, Domperidone, Colestyramine.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic Reinforcement (additive sympathetic effects); Pharmacodynamic Antagonism (inhibition of blood pressure-lowering effects); Pharmacokinetic Clearance Alteration (decreased Pseudoephedrine elimination); Altered Absorption rate of Acetaminophen.
Timing-based interaction rules (if applicable): Co-administration with an MAOI is contraindicated and must be separated by a mandatory period of 14 days following discontinuation of the MAOI.
Population-specific interaction notes (if applicable): Interaction severity and the hazard of accumulation are stated as greater in patients with severe hepatic or renal impairment.
Interaction-related restrictions: Strictly prohibited from co-administration with other acetaminophen-containing medicines or any Monoamine Oxidase Inhibitors.

Interaction classifications (high-level)

The profile classifies interactions into Contraindicated Combinations (e.g., MAOIs) and Significant Interactions (e.g., agents affecting blood pressure and anticoagulation). The regulatory basis for these restrictions is documented in official government monographs, including those from the FDA and various national health authorities. The constraints define that the risk of severe liver damage with Alcohol is linked to chronic consumption, and the enhanced anticoagulant effect with Warfarin is linked to prolonged regular daily use of the Acetaminophen component.

Resulting interaction structure

Official interaction statements:

• The combination with an MAOI is formally documented as contraindicated due to the risk of severe hypertensive reactions.
• Co-administration with other sympathomimetic agents is restricted to prevent additive pharmacodynamic effects that could result in increased blood pressure.
• The Acetaminophen component may enhance the anticoagulant effect of Warfarin with prolonged, regular use.
• Urinary alkalinizing agents decrease the elimination rate of Pseudoephedrine, resulting in increased systemic exposure.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documents define this product’s interaction structure by mandating strict prohibitions against combinations that cause pharmacodynamic reinforcement, such as MAOIs, and against simultaneous intake of other Acetaminophen products to mitigate organ-specific toxicity. The profile further details substances that alter the systemic clearance of the decongestant and analgesic components, which informs the overall classification of clinically significant drug interactions documented in official government labeling.

How Coldrex Head Cold Works — Mechanism of Action

This medication modulates physiological processes through three distinct mechanisms. The paracetamol component acts as an inhibitor of cyclooxygenase (COX) enzymes within the central nervous system (CNS), reducing the synthesis of prostaglandins (PGE2) in the hypothalamus. This action results in a lowering of the thermoregulatory set point (antipyresis) and an alteration of afferent pain signal transmission.

Simultaneously, phenylephrine functions as an agonist at alpha1-adrenergic receptors on nasal blood vessel smooth muscle. This interaction initiates a cascade causing vasoconstriction, which physically reduces the vascular volume and fluid accumulation in the nasal lining. This physiological consequence limits the vascular component of the nasal obstruction and increases the cross-sectional area of the airway.

Finally, promethazine acts as an antagonist at Histamine H1 receptors centrally and peripherally. This suppresses histamine-driven increases in vascular permeability and secretory activity. Its activity in the CNS leads to CNS depression and a change in the state of arousal by modulating central pathways.

Administration and Route

The combination medicine is designed for oral administration, available as solid forms like tablets or caplets, as well as granules contained in sachets. When the sachet form is used, the contents must be dissolved in a sufficient amount of water before ingestion. The dosage protocol mandates a strict minimum interval of four hours between any two administrations, a scheduling requirement designed to maintain the therapeutic presence of the active ingredients while preventing accumulation.

Standard Dosing and Maximum Limits

For adults and adolescents 12 years and older, the standard dose is one to two tablets per administration, taken every four to six hours as necessary. The total daily intake must adhere to a crucial restriction: patients must not exceed eight tablets of the standard strength formulation in any 24-hour period. This limit is enforced to comply with the established 4 gram maximum for the Paracetamol component.

Duration and Special Use Principles

Administration of this product is designated for short-term use only, and the instructions specify that the treatment duration should not continuously exceed seven days without seeking professional consultation. A primary instruction of the usage protocol is the prohibition against administering this product concurrently with any other medicine containing Paracetamol or similar cold and flu ingredients, a measure intended to prevent cumulative overdose. Furthermore, specific adjustments are noted for certain populations; patients with moderate to severe renal or hepatic impairment may require a reduced dose or a prolongation of the dosing interval.

Research evidence / Overview of Studies for Coldrex Head Cold

Evidence for use in Symptomatic Relief of the Common Cold

Research examining this dual combination primarily centers on short-term, placebo-controlled, double-blind Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies monitor outcomes related to physical discomfort in otherwise healthy adults using patient-reported measures, such as the Total Symptom Score (TSS).

Findings from these trials indicate that studies reported patterns showing changes in patient-reported global assessment scores compared to placebo over the initial short-term follow-up period. However, evidence quality varies across studies, and findings regarding changes for some secondary cold symptoms, such as cough and sneezing, were often reported to be inconsistent or inconclusive across the synthesized trials.

Evidence for Relief of Pain and Fever

Research exploring this area relies substantially on the evidence base for the Acetaminophen component, which was studied in contexts involving physiological strain. Studies monitored the change from baseline in self-reported severity of headache and body aches. Research describes patterns observed in the studies related to changes in temperature in febrile patients and differences in pain scores that researchers examined when the active analgesic agent was compared to placebo. However, the research does not always specifically isolate the contribution of the analgesic to relief within the combination tablet versus the single-ingredient product.

Evidence for Relief of Nasal and Sinus Congestion

Studies exploring the decongestant component were conducted using short-term, placebo-controlled RCTs. Researchers used both patient-reported outcomes describing perceived discomfort and objective measures of nasal airflow conductance in some trials. Findings indicate that studies reported measured differences in nasal airflow and changes in self-reported severity scores for nasal congestion within the first few hours after a single dose. The evidence is limited regarding the sustained symptom management of the decongestant component beyond single-dose or short-term (up to 3-day) use.

What is Still Uncertain About the Research

The existing evidence landscape assesses acute changes, meaning research confirms that follow-up durations were limited in the core clinical trials for the combination product. Long-term effects are not fully established, and evidence remains limited in individuals with pre-existing conditions that may affect research outcomes. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions and group patterns under which they were conducted, and results apply only to the populations studied.

Common questions about Coldrex Head Cold (FAQ)

Q: Can Coldrex Head Cold make you sleepy?

A: Official information indicates that combination products containing similar ingredients may list dizziness or drowsiness as possible side effects. Furthermore, regulatory labeling for combination products that include an antihistamine component (an H1 antagonist) indicates that drowsiness is a possible effect due to activity in the central nervous system.

Q: How long does the effect of Coldrex Head Cold usually last?

A: The active ingredients in the standard, immediate-release formulation are typically administered every 4 to 6 hours. This interval is defined in the regulatory dosage guides, corresponding to how long the medicine's effects are typically present.

Q: Can I use Coldrex Head Cold if I am over 65 years old?

A: Official product information states that use in older adults (the geriatric population) is subject to specific caution. Official guidance indicates that older adults may be more sensitive to the drug’s effects, and specific caution is noted regarding effects such as dizziness or difficulty urinating.

Q: Can Coldrex Head Cold affect my ability to drive or operate machinery?

A: Official product warnings advise that caution should be exercised when operating a motor vehicle or machinery. This is due to possible side effects like dizziness or drowsiness. Official warnings state that a person should wait to see how the medicine affects them before engaging in activities that require alertness.

Q: Is Coldrex Head Cold suitable for people with asthma?

A: Official labeling advises that individuals with pre-existing conditions like asthma or other breathing disorders should consult a healthcare professional before using this medicine.

Q: Are the ingredients in Coldrex Head Cold addictive?

A: The primary decongestant ingredient, Pseudoephedrine, is not classified as a controlled drug under regulatory law. Official information describes that when the medicine is used as directed for short-term symptomatic relief, it is not considered addictive; however, regulatory information acknowledges that misuse may be associated with behaviors linked to dependence.

Q: Can a person with diabetes use Coldrex Head Cold?

A: Official prescribing information indicates that people with diabetes mellitus should use the medicine with caution. Such individuals should seek consultation with a healthcare professional before use, as the decongestant component may interact with their condition.

Q: Is there a link between Coldrex Head Cold and restlessness or anxiety?

A: Yes, official regulatory labels list restlessness and anxiety under documented side effects, particularly relating to the decongestant component. Insomnia (difficulty sleeping) is also commonly documented among psychiatric disorders.

Q: Why is it called 'Head Cold' and not just 'Cold'?

A: The medicine is officially indicated for the symptomatic relief of nasal/sinus congestion with headache, fever, and pain associated with the common cold. The combination of ingredients specifically targets symptoms concentrated in the head and upper respiratory areas.

Q: Are there any common foods or drinks I should avoid while using this medicine?

A: Regulatory warnings emphasize avoiding the co-administration of alcohol. Some product information suggests taking the medicine with food or milk to help prevent stomach upset.

Q: Is Coldrex Head Cold safe to use if I have an existing kidney problem?

A: Official documents define that severe renal impairment (severe kidney problems) is a contraindication for use. Caution is specifically required when administering the medicine to patients with moderate renal impairment.

Q: Can I take Coldrex Head Cold if I'm currently using herbal supplements?

A: Regulatory guidance notes that there is not enough information to confirm whether complementary medicines, herbal remedies, and supplements are safe to take with the active ingredients. Consultation with a healthcare professional is advised due to lack of testing for interactions.

Q: Is it normal to feel a bit dizzy after using Coldrex Head Cold?

A: Dizziness is listed in official documentation as a known possible side effect of the medicine's ingredients. If a person experiences severe dizziness, official warnings state they should stop using the medicine.

Q: Are there different versions of Coldrex Head Cold for day and night?

A: Many combination cold and flu medicines containing similar ingredients are available in separate Day and Night formulations. Nighttime versions typically include an added antihistamine ingredient to address symptoms like sneezing and runny nose, which may cause drowsiness.

Q: What if I forget to take my scheduled amount of Coldrex Head Cold?

A: Official regulatory guidance regarding a missed dose states that a person may take it as soon as they remember. If it is almost time for the next scheduled dose, the missed dose is generally skipped, and the regular schedule is continued. The guidance emphasizes that a person should avoid taking double doses.

Q: What should I look out for if I think Coldrex Head Cold is causing a reaction?

A: Official warnings describe a list of serious symptoms that warrant stopping the medicine and seeking immediate medical attention. These include signs of an allergic reaction (rash, swelling), dangerously high blood pressure (severe headache), fast/irregular heartbeat, or signs of liver problems (dark urine, yellowing of skin/eyes).

Q: How does Coldrex Head Cold compare to simple paracetamol tablets?

A: The key difference is the combination of ingredients. Simple Paracetamol is indicated only for pain relief and fever reduction. The combination product adds a decongestant component, Pseudoephedrine, which is indicated for the temporary relief of nasal congestion and sinus pressure.

Q: Can Coldrex Head Cold cause skin rash or itching?

A: Yes, official regulatory labels list skin rash and itching as possible adverse effects. Severe forms of skin reactions, such as Stevens-Johnson Syndrome (SCARs), are also documented as serious safety considerations.

Q: Is Coldrex Head Cold appropriate for children under 12?

A: The medicine is contraindicated or not recommended for use in children under 12 years of age. Official regulatory warnings note that cough and cold products have not been reliably shown to be safe or effective in young children and may cause serious side effects.

Q: Does Coldrex Head Cold contain pseudoephedrine or phenylephrine?

A: The medicine is defined as containing Pseudoephedrine hydrochloride as the decongestant component alongside Acetaminophen. The official pharmacological classification and interaction profile are based on this specific ingredient combination.

Q: Can Coldrex Head Cold be taken with caffeine-containing beverages?

A: Both the active decongestant ingredient and caffeine are substances that can affect blood pressure and heart rate. Regulatory sources advise consultation with a healthcare professional, as combining the two may potentially enhance these effects.

Q: Are there any long-term side effects noted for Coldrex Head Cold?

A: This product is officially designated for short-term use only, and the treatment duration should not continuously exceed seven days. The safety profile focuses on the effects observed during this short-term period, and the long-term safety profile is not fully established in the core clinical trials.

Q: How is Coldrex Head Cold absorbed by the body?

A: The active ingredients are rapidly and completely absorbed into the bloodstream after oral administration. The medicine is then primarily eliminated from the body via the urine, a process known as excretion.

Q: Can Coldrex Head Cold make me thirsty?

A: Official regulatory labels list dry mouth as a possible side effect of the medicine's ingredients. Dry mouth is a known side effect listed in official regulatory labels.

Q: What are the limitations of the research on Coldrex Head Cold?

A: The evidence landscape primarily confirms effects over a short duration, meaning follow-up periods were limited in core clinical trials. The evidence also remains limited in individuals who have pre-existing health conditions that may affect research outcomes.

Q: Can I use Coldrex Head Cold if I also have hay fever?

A: The medicine's decongestant component is officially indicated to temporarily relieve nasal congestion caused by the common cold or upper respiratory allergies, which includes hay fever.

Q: Is the combination of ingredients in Coldrex Head Cold common?

A: Combinations containing Pseudoephedrine along with an analgesic or antipyretic component are well-established and have been authorized and used in many regions for over 35 years for the symptomatic relief of cold and flu symptoms.

Coldrex Head Cold tablets must be stored and disposed of according to strict official guidelines to ensure stability and safety.

Storage Requirements

Scope Element	Requirement
Temperature	Store below 25 C at controlled room temperature.
Protection	Keep in a dry place, protected from excessive moisture and light.
Child Safety	Must be kept out of the sight and reach of children.

The medicine should remain in its original container and must not be used after the printed expiry date. Storage areas prone to heat and humidity, such as bathrooms, should be avoided.

Disposal Instructions

Official disposal rules strictly prohibit discarding unused or expired Coldrex tablets in wastewater or household waste. The individual is required to consult a pharmacist for instructions on proper pharmaceutical waste disposal. This ensures the product is discarded safely and prevents environmental contamination.